AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 201 filers reported holding AGIOS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,970,000 | -12.6% | 120,000 | 0.0% | 0.05% | -23.3% |
Q2 2023 | $3,398,400 | +29.7% | 120,000 | +5.2% | 0.06% | +17.6% |
Q1 2023 | $2,620,555 | +55.5% | 114,086 | +90.1% | 0.05% | +96.2% |
Q4 2022 | $1,684,800 | -58.9% | 60,000 | -58.6% | 0.03% | -54.4% |
Q3 2022 | $4,100,000 | -8.6% | 145,000 | -5.8% | 0.06% | +5.6% |
Q1 2022 | $4,484,000 | +4.1% | 154,000 | +17.6% | 0.05% | +12.5% |
Q4 2021 | $4,308,000 | -34.3% | 131,000 | +10.1% | 0.05% | -44.2% |
Q2 2021 | $6,560,000 | +62.9% | 119,000 | +52.6% | 0.09% | -1.1% |
Q1 2021 | $4,028,000 | -4.2% | 78,000 | -19.6% | 0.09% | -9.4% |
Q4 2020 | $4,204,000 | +13.2% | 97,000 | -8.5% | 0.10% | +11.6% |
Q3 2020 | $3,713,000 | -34.5% | 106,000 | 0.0% | 0.09% | -54.5% |
Q2 2020 | $5,671,000 | +188.2% | 106,000 | +91.0% | 0.19% | +70.3% |
Q1 2020 | $1,968,000 | -43.9% | 55,500 | -24.5% | 0.11% | -5.9% |
Q4 2019 | $3,508,000 | -68.7% | 73,500 | -78.7% | 0.12% | -79.8% |
Q3 2019 | $11,194,000 | – | 345,600 | – | 0.58% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Rock Springs Capital Management LP | 2,661,605 | $61,137,067 | 1.46% |
Bellevue Group AG | 4,013,500 | $92,190,095 | 1.34% |
Eagle Health Investments LP | 267,630 | $6,147,461 | 1.20% |
ARMISTICE CAPITAL, LLC | 3,460,000 | $79,476,200 | 1.14% |
Integral Health Asset Management, LLC | 213,000 | $4,892,610 | 0.99% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 454,000 | $10,428,380 | 0.44% |
ArrowMark Colorado Holdings LLC | 1,557,705 | $35,780,484 | 0.41% |
FARALLON CAPITAL MANAGEMENT LLC | 2,092,829 | $48,072,282 | 0.27% |
Virtus ETF Advisers LLC | 9,932 | $228,138 | 0.13% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 614,533 | $14,115,823 | 0.09% |